Symposium / Summit

PEGS Europe: Protein & Antibody Engineering Summit

Date

Tuesday, November 2, 2021 - Thursday, November 4, 2021

Location

Barcelona, Spain & Virtual
Attendee at PEGS Europe: Protein & Antibody Engineering Summit

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Nearly 1,300 delegates from 40 countries, including 75% from pharma and biotech organizations, last convened in-person in Lisbon in 2019 to discuss the latest advancements in protein and antibody engineering.

We are pleased to provide two half hour presentations during the Engineering Antibodies program on Wednesday, November 3rd and during the Library and Technologies Track on Tuesday, November 2nd.

 

 

Sophie Vermond Headshot

Assessing Efficacy and Potential Safety Risks of Cell Therapies In Vitro Using Primary and iPSC-Derived Cells

Sophie Vermond, Early Discovery Scientist, Immunology, Immuno-oncology and Cell Therapy, Charles River Labs

Engineering Antibodies Track | Wednesday, November 3, 2021, from 8am - 8:30 (GMT)

Within cell therapy development the use of in vivo animal models can present significant hurdles in translatability to humans. As a result, the establishment of complementary high-quality in vitro efficacy and safety studies to foster the development of such therapies has become critical before filing for Investigational New Drug (IND) status. Charles River has developed an in vitro efficacy package aimed at determining cell therapy activity, specificity and potency. In addition, we are able to generate an in vitro safety profile using primary and iPSC-derived cells.

Jean-Philippe Buerckert Headshot

The Cosmic Antibody Library – Displaying Over 100 Billion Exclusive Paratopes on Therapeutically Favorable, Unmutated Scaffolds

Jean-Philippe Buerckert, PhD, Director of Bioinformatics, Large Molecule Discovery, Charles River Labs

Library and Technologies Track | Tuesday, November 2, 2021, from 9:30am - 10:00 (GMT)

The Cosmic Antibody Library – Displaying Over 100 Billion Exclusive Paratopes on Therapeutically Favorable, Unmutated Scaffolds

Charles River’s antibody discovery platforms have delivered sequence-unique binders to every target panned in over 80 campaigns. Their true paratope diversity reliably yielded binders against difficult targets like ion channels, ultra-specific pMHC complex binders, GPCRs, immune-oncology targets, bnAbs, and more. Our new Cosmic antibody library encompasses over 100 billion computationally optimized, fully human antibodies. Its increased diversity will eclipse the previous, unprecedented discovery achievements and is offered with guaranteed molecular exclusivity.

 

IND-enabling Specificity Studies for Antibody and CAR T Cell Therapeutics Using Human Cell Microarray Technology 

Diogo Rodrigues PhD, Senior Client Manager, Retrogenix A Charles River Company 

Library and Technologies Track | Tuesday, November 2, 2021, from 9:30am - 10:00 (GMT)